179 related articles for article (PubMed ID: 37307690)
1. Influence of physicians' risk perception on switching treatments between high- efficacy and non-high-efficacy disease‑modifying therapies in multiple sclerosis.
Seifer G; Arun T; Capela C; Laureys G; Jones E; Dominguez-Castro P; Sanchez-de la Rosa R; Hiltl S; Iaffaldano P
Mult Scler Relat Disord; 2023 Aug; 76():104770. PubMed ID: 37307690
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry.
Iaffaldano P; Lucisano G; Guerra T; Patti F; Cocco E; De Luca G; Brescia Morra V; Pozzilli C; Zaffaroni M; Ferraro D; Gasperini C; Salemi G; Bergamaschi R; Lus G; Inglese M; Romano S; Bellantonio P; Di Monte E; Maniscalco GT; Conte A; Lugaresi A; Vianello M; Torri Clerici VLA; Di Sapio A; Pesci I; Granella F; Totaro R; Marfia GA; Danni MC; Cavalla P; Valentino P; Aguglia U; Montepietra S; Ferraro E; Protti A; Spitaleri D; Avolio C; De Riz M; Maimone D; Cavaletti G; Gazzola P; Tedeschi G; Sessa M; Rovaris M; Di Palma F; Gatto M; Cargnelutti D; De Robertis F; Logullo FO; Rini A; Meucci G; Ardito B; Banfi P; Nasuelli D; Paolicelli D; Rocca MA; Portaccio E; Chisari CG; Fenu G; Onofrj M; Carotenuto A; Ruggieri S; Tortorella C; Ragonese P; Nica M; Amato MP; Filippi M; Trojano M;
J Neurol; 2024 Mar; 271(3):1150-1159. PubMed ID: 38135850
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D
Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Bonafede MM; Johnson BH; Wenten M; Watson C
Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
[TBL] [Abstract][Full Text] [Related]
5. Is the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?
Krämer J; Tenberge JG; Kleiter I; Gaissmaier W; Ruck T; Heesen C; Meuth SG
PLoS One; 2017; 12(4):e0174858. PubMed ID: 28406921
[TBL] [Abstract][Full Text] [Related]
6. Switching patients at high risk of PML from natalizumab to another disease-modifying therapy.
Giovannoni G; Marta M; Davis A; Turner B; Gnanapavan S; Schmierer K
Pract Neurol; 2016 Oct; 16(5):389-93. PubMed ID: 27114560
[TBL] [Abstract][Full Text] [Related]
7. High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing-Remitting Multiple Sclerosis.
Freeman L; Longbrake EE; Coyle PK; Hendin B; Vollmer T
CNS Drugs; 2022 Dec; 36(12):1285-1299. PubMed ID: 36350491
[TBL] [Abstract][Full Text] [Related]
8. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis.
Manzano A; Eskyté I; Ford HL; Pavitt SH; Potrata B; Schmierer K; Chataway J; Webb EJD; Meads D; Pepper G; Bekker HL
Mult Scler Relat Disord; 2020 Nov; 46():102507. PubMed ID: 32979733
[TBL] [Abstract][Full Text] [Related]
9. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
[TBL] [Abstract][Full Text] [Related]
10. Treatment switches of disease-modifying therapies in people with multiple sclerosis: long-term experience from the German MS Registry.
Frahm N; Ellenberger D; Stahmann A; Fneish F; Lüftenegger D; Salmen HC; Schirduan K; Schaak TPA; Flachenecker P; Kleinschnitz C; Paul F; Krefting D; Zettl UK; Peters M; Warnke C
Ther Adv Neurol Disord; 2024; 17():17562864241239740. PubMed ID: 38560408
[TBL] [Abstract][Full Text] [Related]
11. Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Freeman L; Kee A; Tian M; Mehta R
Drugs Real World Outcomes; 2021 Dec; 8(4):497-508. PubMed ID: 34136997
[TBL] [Abstract][Full Text] [Related]
12. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
Neuberger EE; Abbass IM; Jones E; Engmann NJ
Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns and persistence on disease modifying therapies for multiple sclerosis and its associated factors.
Cárdenas-Robledo S; Arenas-Vargas LE; Arenas RD; Gaspar-Toro JM; Muñoz-Rosero ÁM; Tafur-Borrero AH; Marín-Medina DS; Acosta-Fajardo HA; Guío-Sánchez C; López-Reyes L
BMC Neurol; 2024 Apr; 24(1):108. PubMed ID: 38566012
[TBL] [Abstract][Full Text] [Related]
14. Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients.
Heesen C; Kleiter I; Meuth SG; Krämer J; Kasper J; Köpke S; Gaissmaier W
J Neurol Sci; 2017 May; 376():181-190. PubMed ID: 28431609
[TBL] [Abstract][Full Text] [Related]
15. Socioeconomic status and disease-modifying therapy prescribing patterns in people with multiple sclerosis.
Reyes S; Suarez S; Allen-Philbey K; Yildiz Ö; Mathews J; Anjorin G; Edwards F; Jain C; Turner B; Marta M; Gnanapavan S; Schmierer K; Giovannoni G
Mult Scler Relat Disord; 2020 Jun; 41():102024. PubMed ID: 32143179
[TBL] [Abstract][Full Text] [Related]
16. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
[TBL] [Abstract][Full Text] [Related]
17. Reasons to switch: a noninterventional study evaluating immunotherapy switches in a large German multicentre cohort of patients with relapsing-remitting multiple sclerosis.
Mäurer M; Tiel-Wilck K; Oehm E; Richter N; Springer M; Oschmann P; Manzel A; Hieke-Schulz S; Zingler V; Kandenwein JA; Ziemssen T; Linker RA
Ther Adv Neurol Disord; 2019; 12():1756286419892077. PubMed ID: 31903096
[TBL] [Abstract][Full Text] [Related]
18. Treatment Patterns Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy.
Bowen J; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
Adv Ther; 2020 Jul; 37(7):3163-3177. PubMed ID: 32436028
[TBL] [Abstract][Full Text] [Related]
19. Temporal and spatial patterns in the prescriptions of disease-modifying therapies for multiple sclerosis. Results from the Italian Multiple Sclerosis and Related Disorders Register.
Lepore V; Paletta P; Bosetti C; Santucci C; Ponzio M; Pupillo E; Leone MA; Bergamaschi R; Mosconi P;
Mult Scler Relat Disord; 2024 Jul; 87():105638. PubMed ID: 38713966
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study.
Lenz F; Harms L
Adv Ther; 2020 Jun; 37(6):2999-3009. PubMed ID: 32333326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
